ResoTher Pharma is pleased to announce that the company has been awarded an Innobooster grant in the amount of DKK 4.900.000 from the Danish Innovation Foundation. The award will fund the continued development of RTP-026, a novel peptide FPR2 agonist.  RTP-026 has shown impressive efficacy and potency in pre-clinical models and is both safe and well tolerated, providing an excellent therapeutic index. The Innobooster award will pave the way for success towards clinical entry of the asset, expected in Q4 2020.
About the Innovation Foundation: The Danish Innovation Foundation supports strategic research and innovation projects across the nation, with offices in Copenhagen, Århus and Ålborg. For more information visit